Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMS NASDAQ:AGRX NASDAQ:MBIO NASDAQ:NCNA NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AAGRXAgile Therapeutics$1.51$1.49$0.20▼$2.63$10.35M1.58352,864 shs120,938 shsMBIOMustang Bio$2.65-1.1%$1.36$0.89▼$24.00$11.73M2.161.60 million shs1.44 million shsNCNANuCana$0.05-15.9%$0.10$0.03▼$10.79$360K1.4248.70 million shs220.74 million shsXERSXeris Biopharma$5.11-3.0%$4.74$2.10▼$6.07$824.15M0.662.06 million shs1.52 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AGRXAgile Therapeutics0.00%0.00%0.00%0.00%+5.59%MBIOMustang Bio-1.12%+118.11%+107.03%+90.65%-88.02%NCNANuCana-15.91%-8.89%-69.58%-93.31%-98.35%XERSXeris Biopharma-3.04%+7.47%+16.67%+22.84%+137.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAGRXAgile TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio1.1463 of 5 stars0.05.00.00.02.90.00.6NCNANuCana3.3446 of 5 stars3.33.00.00.03.32.51.3XERSXeris Biopharma3.8576 of 5 stars2.43.00.04.22.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas Pharmaceuticals 0.00N/AN/AN/AAGRXAgile Therapeutics 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/ANCNANuCana 2.50Moderate Buy$25.0049,700.80% UpsideXERSXeris Biopharma 2.83Moderate Buy$6.2522.31% UpsideCurrent Analyst Ratings BreakdownLatest XERS, NCNA, AGRX, ADMS, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49AGRXAgile Therapeutics$19.98M0.52N/AN/A($5.51) per share-0.27MBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/ANCNANuCanaN/AN/AN/AN/A$1.34 per shareN/AXERSXeris Biopharma$203.07M3.94N/AN/A($0.20) per share-25.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/AAGRXAgile Therapeutics-$14.47M-$3.65N/A∞N/A-36.24%N/A-147.37%N/AMBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)NCNANuCana-$24.28M-$7.02N/AN/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)XERSXeris Biopharma-$54.84M-$0.30N/AN/AN/A-20.25%N/A-12.07%8/6/2025 (Estimated)Latest XERS, NCNA, AGRX, ADMS, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025NCNANuCana-$0.0129-$0.63-$0.6171-$0.63N/AN/A5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/A5/8/2025Q1 2025XERSXeris Biopharma-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AAGRXAgile TherapeuticsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17AGRXAgile TherapeuticsN/A0.560.38MBIOMustang BioN/A1.341.34NCNANuCanaN/A1.251.25XERSXeris BiopharmaN/A1.721.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%AGRXAgile Therapeutics10.92%MBIOMustang Bio9.95%NCNANuCana44.00%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%AGRXAgile Therapeutics0.50%MBIOMustang Bio0.21%NCNANuCana31.20%XERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableAGRXAgile Therapeutics306.86 million6.82 millionNot OptionableMBIOMustang Bio1004.38 million4.37 millionNot OptionableNCNANuCana306.08 million4.18 millionNot OptionableXERSXeris Biopharma290156.38 million146.27 millionOptionableXERS, NCNA, AGRX, ADMS, and MBIO HeadlinesRecent News About These CompaniesXeris Biopharma Holdings, Inc. (XERS) - Yahoo FinanceJuly 10 at 3:36 AM | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Trading 7.4% Higher - Time to Buy?July 9 at 6:03 PM | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 28, 2025 | marketbeat.comXeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term InvestingJune 18, 2025 | seekingalpha.comXeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying ActivityJune 17, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 SharesJune 17, 2025 | insidertrades.comKevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) StockJune 16, 2025 | marketbeat.comXeris Biopharma touts ambitious growth plan, promising hypothyroidism drugJune 4, 2025 | chicagobusiness.comCXeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor DayJune 3, 2025 | finance.yahoo.comXeris Announces Details for Analyst & Investor DayMay 20, 2025 | businesswire.comXeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in NowMay 12, 2025 | msn.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comXeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...May 9, 2025 | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comXeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comXeris Biopharma Reports Record First Quarter 2025 Financial ResultsMay 8, 2025 | businesswire.com4XERS : Earnings Outlook For Xeris Biopharma HoldingsMay 7, 2025 | benzinga.comXeris Biopharma Holdings: Looking For More Growth In Q1 EarningsMay 7, 2025 | seekingalpha.comXeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025May 2, 2025 | seekingalpha.comXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To ProfitApril 26, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?April 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXERS, NCNA, AGRX, ADMS, and MBIO Company DescriptionsAdamas Pharmaceuticals NASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Agile Therapeutics NASDAQ:AGRXAgile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.Mustang Bio NASDAQ:MBIO$2.65 -0.03 (-1.12%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.66 +0.01 (+0.42%) As of 07/11/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.NuCana NASDAQ:NCNA$0.05 -0.01 (-15.91%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.05 +0.00 (+0.60%) As of 07/11/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Xeris Biopharma NASDAQ:XERS$5.11 -0.16 (-3.04%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$5.08 -0.03 (-0.59%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
